Y-mAbs Therapeutics Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Y-Mabs Therapeutics, Inc. |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials
TL;DR
Y-mAbs Q1 2025 10-Q filed. Pharma company in NJ.
AI Summary
Y-mAbs Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company is involved in the pharmaceutical preparations industry, with its headquarters located in Princeton, NJ. Key financial data and operational details are presented in this filing.
Why It Matters
This filing provides investors and stakeholders with an update on Y-mAbs Therapeutics' financial health and operational status for the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Y-mAbs Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- $248,000 — Operating Lease Liability Current (Represents current operating lease liabilities as of March 31, 2025.)
- $248,000 — Operating Lease Liability Noncurrent (Represents noncurrent operating lease liabilities as of March 31, 2025.)
Key Players & Entities
- Y-mAbs Therapeutics, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250513 (date) — Filing date of the report
- Princeton, NJ (location) — Location of the company's business and mailing address
- 646-885-8505 (phone_number) — Business phone number
FAQ
What is the primary business of Y-mAbs Therapeutics, Inc.?
Y-mAbs Therapeutics, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].
When was the 10-Q report filed?
The 10-Q report was filed on May 13, 2025.
What is the fiscal year end for Y-mAbs Therapeutics, Inc.?
The fiscal year end for Y-mAbs Therapeutics, Inc. is December 31.
Where is Y-mAbs Therapeutics, Inc. located?
Y-mAbs Therapeutics, Inc. is located in Princeton, NJ.
What are the reported operating lease liabilities for the period ending March 31, 2025?
The company reported $248,000 for both current and noncurrent operating lease liabilities.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Y-mAbs Therapeutics, Inc..